Potential conflict of interest: Nothing to report.
Bayesian prediction for liver fibrosis staging: Combined use of elastography and serum fibrosis markers†
Article first published online: 26 APR 2013
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 58, Issue 1, pages 450–451, July 2013
How to Cite
Motosugi, U., Ichikawa, T., Araki, T., Matsuda, M., Fujii, H. and Enomoto, N. (2013), Bayesian prediction for liver fibrosis staging: Combined use of elastography and serum fibrosis markers. Hepatology, 58: 450–451. doi: 10.1002/hep.26144
- Issue published online: 24 JUN 2013
- Article first published online: 26 APR 2013
- Accepted manuscript online: 21 NOV 2012 03:01PM EST
- Manuscript Accepted: 3 OCT 2012
- Manuscript Revised: 19 SEP 2012
To the Editor:
Liver elastography, using ultrasound transient elastography (UTE) or magnetic resonance elastography (MRE), and serum fibrosis markers have been used separately to predict liver fibrosis stage in chronic liver disease.1, 2 Combined use of elastography and fibrosis markers may be a superior method. Algorithms for combined use of serum markers and elastography have been proposed, with specific cut-off values being used in the decision trees.3-5 However, a cut-off value for staging always involves a compromise between sensitivity and specificity. The use of Bayesian prediction to stage liver fibrosis involves calculating the stage based on elastographic or serum biomarker measures (see Appendix). The probability of a certain fibrosis stage can be calculated after obtaining the stiffness value of the patient's liver or the aspartate aminotransferase-to-platelet ratio index (APRI) value.
Table 1 shows the results of fibrosis stage prediction in 20 patients who underwent liver resection and had elastography (both MRE and UTE) and serum fibrosis biomarkers before surgery. Histological fibrosis stage is shown by the METAVIR score. Respective cut-off values for the APRI, UTE, and MRE were 0.5, 5.2, and 3.2 kPa for significant fibrosis (≥F2) and 2.0, 12.9, and 4.6 kPa for cirrhosis (F4).6, 7 Accuracy of fibrosis staging was compared between APRI and APRI with UTE and between APRI and APRI with MRE using Bayesian methods. The Bayesian method successfully combined APRI and UTE/MRE, with a significant increase in accuracy; the decision-tree cut-off method failed to increase accuracy after combining elastography with APRI.
|For Significant Fibrosis (≥F2)||APRI||APRI+UTE||APRI+MRE|
|Accuracy (%)||75 (15/20)||80 (16/20)||70 (14/20)|
|P value versus APRI||Control||0.317||0.706|
|Accuracy (%)||60 (12/20)||80 (16/20)||80 (16/20)|
|P value versus APRI||Control||0.046||0.046|
|For cirrhosis (F4)||APRI||APRI+UTE||APRI+MRE|
|Accuracy (%)||65 (13/20)||65 (13/20)||65 (13/20)|
|P value versus APRI||Control||1.000||1.000|
|Accuracy (%)||60 (12/20)||65 (13/20)||90 (18/20)|
|P value versus APRI||Control||0.317||0.014|
An advantage of Bayesian prediction over the cut-off method is its applicability over a range of conditions. Once the mean and standard deviation (SD) of various elastographic and serum fibrosis markers have been determined, a combinational probability estimate can be obtained for the fibrosis stage. Furthermore, the Bayesian prediction provides probabilities, rather than a yes/no decision (Fig. 1), allowing the predicted stage to be questioned if the associated probability is too low. The Bayesian method also allows weighting of the different methods. A small SD indicates a method with high validity, and the Bayesian prediction reflects the SD in the probability.
A limitation of this approach is the assumed normal distribution of values returned by each method. However, the use of Bayesian prediction, incorporating relevant findings from the available methods, is a promising technique for accurate liver fibrosis staging.
A Bayesian prediction model for liver fibrosis staging, including a detailed explanation of the model, is available at http://yamarad.umin.ne.jp/bayesian/.
- 1Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350., , , , , , et al.
- 2Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 32-40., , , , , , et al.
- 3Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. HEPATOLOGY 2012; 55: 58-67., , , , , , .
- 4Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198., , , , , .
- 5ARFI, FibroScan(R), ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol 2012; 57: 281-287., , , , , , et al.
- 6Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Mag Reson Med Sci 2012 (In press)., , , , , , et al.
- 7Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56: 55-62., , , , , , et al.
Utaroh Motosugi M.D.*, Tomoaki IChicahua M.D.*, Tsutomu Araki M.D.*, Masanori Matsuda M.D., HHideki Fujii M.D., Nobuyuki Enomoto M.D., * Department of Radiology University of Yamanashi, Yamanashi, Japan, First Department of Surgery, University of Yamanashi, Yamanashi, Japan, First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan.